Type 1 vs Type 2 MI: Search for Differentiating Biomarkers Proves Fruitless physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
INN takes a closer look at some of the biggest ongoing psychedelic research studies that could shape the future of the industry.
The psychedelics investment proposition is an enticing one for investors, and the bedrock of the industry is the potential attached to clinical research on psychedelic substances.
Thanks to the groundbreaking progress of studies and trials evaluating psychedelic treatments, the entire sector is gaining more attention as a new age of medicine becomes a very real possibility.
Here the Investing News Network presents some of the biggest psychedelic research studies being conducted. They could help boost the visibility of psychedelics as medicine in the future.
Basler Phantomspital – Regierungsrätliche Nebelpetarden um überhöhte Preise bazonline.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bazonline.ch Daily Mail and Mail on Sunday newspapers.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the proteins neurofilament light chain, known as NfL, and glial fibrillary acidic protein, or GFAP, are associated with an increased risk of worsening disability, new research shows.
Measuring levels of certain proteins in the blood can provide important information about a person’s health. NfL is released into the blood when neurons or nerve cells are damaged or destroyed. As such, levels of NfL in the blood are indicative of injury in the nervous system. GFAP, meanwhile, is associated with the activity of star-shaped neural support cells called astrocytes, and also is a marker of nervous system injury.
The Event Will Include Over 30 Video Presentations By Publicly Traded Cannabis Companies in the Hemp and CBD Space
SRAX (NASDAQ:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, will be hosting a cannabis-focused virtual conference, held on April 20th, 2021 (or as some call it, 4/20) from 11:30 AM – 5:00 PM EST. Each company will have 25 minutes to present to a wide-ranging audience of over 500,000 investors. The virtual conference will also host interviews and talks with major Cannabis leaders such as Steve DeAngelo the Co-founder of
Harborside (CSE:HBOR) (OTCQX:HBORF), The Acrview Group, The Last Prisoner Project and the Radio Free Cannabis Podcast.